Cirrhosis News and Research

Latest Cirrhosis News and Research

Daclatasvir has two primary modes of action against HCV

A study by researchers from Los Alamos National Laboratory and a multinational team reveals how daclatasvir, a direct-acting antiviral agent in development for the treatment of hepatitis C virus (HCV), targets one of its proteins and causes the fastest viral decline ever seen with anti-HCV drugs - within 12 hours of treatment.

21 Feb 2013

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).

20 Feb 2013

Study may help design better DAA drug cocktails to treat HCV

Hepatitis C virus (HCV) infection affects about 4 million in the United States and is the primary cause of liver cirrhosis and liver cancer. Current therapy against HCV is suboptimal. Daclatasvir, a direct acting antiviral (DAA) agent in development for the treatment of HCV, targets one of the HCV proteins (i.e., NS5A) and causes the fastest viral decline (within 12 hours of treatment) ever seen with anti-HCV drugs.

20 Feb 2013

Early PBC prognosis advocated

Biochemical response to ursodeoxycholic acid at 6 months is a better predictor for primary biliary cirrhosis prognosis than the current standard of 1 year, study results suggest.

18 Feb 2013

Researchers discover miR-27b that regulates lipid levels in the blood

Researchers have identified a microRNA liver gene, miR-27b, which regulates lipid (cholesterol or fat) levels in the blood. This regulator gene controls multiple genes involved in dyslipidemia-abnormal blood cholesterol levels that can contribute to heart disease.

11 Feb 2013

Donor liver quality: an interview with Dr Eric Orman

Liver transplantation is a surgical procedure in which a liver (or part of a liver) is removed from a donor and placed into a recipient. Although some transplants use a portion of the liver of living donors, the vast majority of donors are deceased.

6 Feb 2013

DHA more effective than EPA in preventing liver inflammation and fibrosis

Research at Oregon State University has found that one particular omega-3 fatty acid has a powerful effect in preventing liver inflammation and fibrosis - common problems that are steadily rising along with the number of Americans who are overweight.

6 Feb 2013

Synageva announces 12-week data from sebelipase alfa Phase I/II study on LAL Deficiency

Synageva BioPharma Corp. (Synageva), a clinical stage biopharmaceutical company developing therapeutic products for rare diseases, today announced publication of the 12-week Phase I/II extension study data of sebelipase alfa in adults with lysosomal acid lipase deficiency (LAL Deficiency) in the online version and an upcoming print edition of Hepatology

5 Feb 2013

Topline results from Gilead’s FISSION and NEUTRINO Phase 3 studies on HCV infection

Gilead Sciences today announced topline results from two Phase 3 studies, FISSION and NEUTRINO, evaluating a 12-week course of the once-daily nucleotide sofosbuvir in combination with ribavirin (FISSION) and in combination with ribavirin and pegylated interferon (NEUTRINO) among treatment-naïve patients with chronic hepatitis C virus (HCV) infection.

5 Feb 2013

Galectin submits GR-MD-02 IND application with FDA for treatment of liver fibrosis

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that it submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) on January 30, 2013.

1 Feb 2013

ArQule, Daiichi Sankyo initiate enrollment in tivantinib Phase 3 trial for hepatocellular carcinoma

Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the pivotal Phase 3 METIV-HCC (MET-high patients with tivantinib in HCC) trial of tivantinib (ARQ 197).

31 Jan 2013

FDA approves Genzyme’s KYNAMRO to treat homozygous familial hypercholesterolemia

Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for KYNAMROTM (mipomersen sodium) injection.

30 Jan 2013

Scientists identify genetic process in which normal liver cells transform into cancerous ones

A team of scientists from the Cancer Science Institute of Singapore (CSI) at the National University of Singapore (NUS) has identified a genetic process in which normal liver cells transform into cancerous ones. The finding provides new understanding into the pathogenesis of human cancers.

29 Jan 2013

Shorter surveillance intervals detect HCC earlier

Hepatocellular carcinoma surveillance in at-risk patients at intervals of less than 6 months picks up smaller tumors compared with longer intervals, show two recently published studies.

28 Jan 2013

Boehringer Ingelheim initiates enrollment in Phase III IFN-free HCV trial

Today, Boehringer Ingelheim announced that the first patients have been enrolled in the company's pivotal Phase III interferon (IFN)-free hepatitis C (HCV) clinical trial programme, HCVerso.

18 Jan 2013

Early hepatitis B vaccination may be ineffective in teenagers

Research reveals that many infants who receive the complete series of hepatitis B virus vaccinations have lost their protection by the time they reach adolescence.

14 Jan 2013

Scientists develop playbook to end devastating impact of fibrotic diseases

A team of scientists has developed a playbook for ending the devastating impact of fibrotic diseases of the liver, lung, kidney, and other organs, which are responsible for as many as 45 percent of all deaths in the industrialized world.

11 Jan 2013

Adolescents may lose hepatitis B virus protection despite vaccination as infants

New research reveals that a significant number of adolescents lose their protection from hepatitis B virus (HBV) infection, despite having received a complete vaccination series as infants. Results in the January 2013 issue of Hepatology, a journal published by Wiley on behalf of the American Association for the Study of Liver Diseases, suggest teens with high-risk mothers (those positive for HBeAg) and teens whose immune system fails to remember a previous viral exposure (immunological memory) are behind HBV reinfection.

8 Jan 2013

PharmaIN receives FDA orphan-drug designation for terlipressin to treat ascites

PharmaIN Corporation and LAT Pharma LLC today announced that the US Food and Drug Administration (FDA) has granted their request for orphan-drug designation for terlipressin for the treatment of ascites due to all etiologies except for cancer.

7 Jan 2013

Raising transfusion threshold improves acute upper GI bleeding outcomes

Outcomes among patients with acute upper gastrointestinal bleeding can be improved by employing a restrictive transfusion strategy that raises the threshold for the transfusion of red cells, the results of a Spanish study indicate.

4 Jan 2013

Cirrhosis News and Research

Latest Cirrhosis News and Research

Daclatasvir has two primary modes of action against HCV

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

Study may help design better DAA drug cocktails to treat HCV

Early PBC prognosis advocated

Researchers discover miR-27b that regulates lipid levels in the blood

Donor liver quality: an interview with Dr Eric Orman

DHA more effective than EPA in preventing liver inflammation and fibrosis

Synageva announces 12-week data from sebelipase alfa Phase I/II study on LAL Deficiency

Topline results from Gilead’s FISSION and NEUTRINO Phase 3 studies on HCV infection

Galectin submits GR-MD-02 IND application with FDA for treatment of liver fibrosis

ArQule, Daiichi Sankyo initiate enrollment in tivantinib Phase 3 trial for hepatocellular carcinoma

FDA approves Genzyme’s KYNAMRO to treat homozygous familial hypercholesterolemia

Scientists identify genetic process in which normal liver cells transform into cancerous ones

Shorter surveillance intervals detect HCC earlier

Boehringer Ingelheim initiates enrollment in Phase III IFN-free HCV trial

Early hepatitis B vaccination may be ineffective in teenagers

Scientists develop playbook to end devastating impact of fibrotic diseases

Adolescents may lose hepatitis B virus protection despite vaccination as infants

PharmaIN receives FDA orphan-drug designation for terlipressin to treat ascites

Raising transfusion threshold improves acute upper GI bleeding outcomes

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Cirrhosis News and Research

Latest Cirrhosis News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in